FGF23 and coronary artery disorder: Nevertheless, the majority of studies on FGF-23 and mortality in CAD patients and after AMI used short- to mid-term mortality as the primary endpoint and so it remains unclear, whether FGF-23 concentrations are also associated with long-term mortality after AMI and whether the effects remain stable over the course of several years.